In Brief: Kensey Nash Angio-Seal
This article was originally published in The Gray Sheet
Executive SummaryKensey Nash Angio-Seal: U.S. approval of the 8 French arterial puncture sealing device "should be forthcoming," the company says July 23 in announcing that FDA's Seattle District has stated that it is "prepared to endorse to FDA headquarters" a pending premarket approval application for the device. The district office's recommendation follows an inspection of the American Home Products facility in Bothell, Washington where the device will be manufactured. Formal approval of the device should follow "pending approval of final labeling," Kensey Nash says. The firm received an approvable letter from FDA in July 1995 for Angio-Seal, which will be marketed domestically by AHP's Sherwood-Davis & Geck subsidiary...
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.